SCHEMBL7044665

SCHEMBL7044665

Cc1ccc(Oc2cc(Br)ccc2C(C)(C)C)c(N)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CYP3A4 P08684 2/20 0.45
SLC6A4 P31645 8/20 0.42
SLC6A2 P23975 6/20 0.41
SLC6A3 Q01959 6/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044839 0.82 GAA (0.40) ALDH1A1PTGDR2L3MBTL1TDP1MAPK1
SCHEMBL17755145 0.80 SLC6A4 (0.55) ALDH1A1CYP3A4SLC6A4SLC6A2SLC6A3
SCHEMBL16344881 0.79 IDO1 (0.41) ALDH1A1CYP3A4SLC6A4SLC6A2SLC6A3
SCHEMBL7044340 0.78 ALDH1A1 (0.39) ALDH1A1SLC6A4SLC6A2SLC6A3PTGDR2
SCHEMBL28734118 0.78 HTT (0.44) ALDH1A1CYP3A4SLC6A4SLC6A2SLC6A3
SCHEMBL28734134 0.77 L3MBTL1 (0.52) ALDH1A1CYP3A4SLC6A4SLC6A2SLC6A3
SCHEMBL29584592 0.77 ALDH1A1 (0.53) ALDH1A1CYP3A4SLC6A4SLC6A2SLC6A3
SCHEMBL7044631 0.77 MEN1 (0.45) ALDH1A1CYP3A4MAPK1SMN1; SMN2MAPT
SCHEMBL7044342 0.74 AR (0.40) ALDH1A1SLC6A4SLC6A2SLC6A3PTGDR2
SCHEMBL28942882 0.73 HTT (0.45) ALDH1A1CYP3A4L3MBTL1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660755-B2 Controlling cell proliferation agent; skin disorders; antiinflamamtory agents ALLERGAN, INC. 2003-12-09 US disclosed
US-20030109687-A1 Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity ALLERGAN, INC. 2003-06-12 US disclosed
US-6455701-B1 SUCH AS 4-((4'-TERT-BUTYL-3'-(4?-TRIFLUOROMETHYL)PHENOXY) PHENYLETHYNYL)BENZOIC ACID; SIDE EFFECT REDUCTION ALLERGAN, INC. 2002-09-24 US disclosed
US-6187950-B1 A REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES ALLERGAN, INC. 2001-02-13 US disclosed
US-5919970-A Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity ALLERGAN SALES, INC. (US) 1999-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109687-A1 Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity RXRB, RXRA, RXRG ALDH1A1 2168/4885CYP3A4 779/4885SLC6A4 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.